11.78
-0.33 (-2.73%)
| Penutupan Terdahulu | 12.11 |
| Buka | 12.05 |
| Jumlah Dagangan | 791,505 |
| Purata Dagangan (3B) | 4,098,489 |
| Modal Pasaran | 1,109,907,200 |
| Harga / Buku (P/B) | 11.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Replimune Group, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.67 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ridgeback Capital Investments L.P. | 30 Jun 2026 | 7,310,656 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Aug 2026 | CNBC | HHS plans new FDA deputy commissioner roles for technology and drugs, sources say |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |